AbbVie Q3 2025 Earnings: Skyrizi and Rinvoq Drive Post-Humira Growth

AbbVie’s Q3 2025 earnings underscore the company’s continued transition in the post-Humira era. Net revenues reached $15.8 billion, up 9.1 percent year over year, driven primarily by immunology and neuroscience. While Humira sales declined sharply, growth from AbbVie’s next-generation immunology blockbusters, Skyrizi and Rinvoq, more than offset this erosion and reinforced the durability of the company’s rebalanced portfolio.

This report summarizes AbbVie’s top medicines by Q3 2025 sales and examines the strategic drivers shaping performance.

AbbVie Q3 2025 Revenue Highlights

• Total net revenues: $15.8B, up 9.1 percent year over year
• Immunology revenues: $7.9B, up 11.9 percent
• Neuroscience revenues: $2.8B, up 20.2 percent
• Combined Skyrizi and Rinvoq sales: over $6.8B, approximately 40 percent year-over-year growth
• Humira sales: $0.99B, down 55 percent year over year

Top 10 AbbVie Medicines by Q3 Sales

Note: Imbruvica sales reflect AbbVie’s reported share and exclude partner revenue.

Immunology: Skyrizi and Rinvoq Define the New Core

Skyrizi generated $4.7 billion in Q3 sales, representing 46.8 percent year-over-year growth. Demand remained strong across its four approved indications: plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. Despite increasing competition within the IL-23 and adjacent pathways, Skyrizi continues to show a clear efficacy advantage. Data from the POETYK PSO trials indicate PASI 90 response rates of approximately 81 to 82 percent for Skyrizi at one year, compared with roughly 44 percent for BMS’s Sotyktu.

Rinvoq delivered $2.2 billion in Q3 sales, up 35.3 percent year over year. Growth was supported by multiple clinical and regulatory milestones, including FDA approval in October 2025 for ulcerative colitis and Crohn’s disease prior to TNF inhibitor use, as well as Phase 3 data across alopecia areata, vitiligo, and rheumatoid arthritis. In the SELECT-SWITCH trial, 43.3 percent of patients achieved low disease activity at week 12 versus 22.4 percent for Humira, reinforcing Rinvoq’s positioning as a broad-spectrum immunology platform.

Humira Decline and Portfolio Rebalancing

Humira sales fell to $993 million in Q3, reflecting a 55 percent year-over-year decline due to biosimilar competition. The pace of erosion highlights the importance of AbbVie’s strategic pivot, with Skyrizi and Rinvoq now firmly established as the company’s primary immunology growth engines.

Neuroscience and Oncology Momentum

Neuroscience delivered double-digit growth, supported by brands such as Vraylar and Ubrelvy. AbbVie also submitted an NDA for tavapadon, a D1 and D5 selective dopamine receptor partial agonist acquired through Cerevel, for Parkinson’s disease. If approved, tavapadon could compete with established dopamine agonists while offering a differentiated mechanism.

In oncology, AbbVie is advancing a new generation of targeted biologics. The BLA for pivekimab sunirine, a CD123-directed antibody-drug conjugate for blastic plasmacytoid dendritic cell neoplasm, is currently under regulatory review.

Strategic Outlook

Recent acquisitions of Capstan Therapeutics and Gilgamesh Pharmaceuticals further illustrate AbbVie’s focus on earlier-stage business development to sustain long-term growth. Capstan adds an in vivo lipid nanoparticle anti-CD19 CAR-T platform for autoimmune diseases, while Gilgamesh contributes a Phase 2 short-acting psychedelic therapy for major depressive disorder. Together, these moves signal AbbVie’s intent to build the next generation of growth drivers beyond its current franchises.

Takeaway

AbbVie’s Q3 2025 results confirm that the company’s post-Humira transition is well underway. Rapid growth from Skyrizi and Rinvoq, expanding neuroscience revenues, and continued investment in oncology and next-generation modalities position AbbVie to sustain growth through the remainder of the decade despite ongoing legacy erosion.